NCT07627074 Weight Loss in Adults Using Semaglutide (Real-world Study)
| NCT ID | NCT07627074 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Novo Nordisk A/S |
| Condition | Overweight |
| Study Type | OBSERVATIONAL |
| Enrollment | 35,000 participants |
| Start Date | 2026-05-12 |
| Primary Completion | 2026-06-01 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 35,000 participants in total. It began in 2026-05-12 with a primary completion date of 2026-06-01.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The purpose of the study is to assess the weight loss in participants treated with commercially available semaglutide according to routine clinical practice at the discretion of the treating physician.
Eligibility Criteria
Inclusion Criteria: * Initiation of semaglutide for weight management during the study period. * Age more than or equal to (≥) 18 at treatment initiation * Baseline body mass index (BMI) ≥27 and less than (\<) 30 kilogram per meter square (kg/m\^2) with at least one weight-related comorbidity, or BMI ≥30 kg/m\^2. * Other inclusion criteria as defined in the protocol are applicable. Exclusion Criteria: * Prior use of glucagon-like peptide-1 receptor agonist (GLP-1 RA) based medication or other obesity management medication (OMMs). * Bariatric surgery at baseline. * Diabetes at baseline. * Pregnancy at baseline.
Contact & Investigator
Clinical Transparency (dept. 2834)
STUDY DIRECTOR
Novo Nordisk A/S
Frequently Asked Questions
Who can join the NCT07627074 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Overweight. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07627074 currently recruiting?
Yes, NCT07627074 is actively recruiting participants. Contact the research team at clinicaltrials@novonordisk.com for enrollment information.
Where is the NCT07627074 trial being conducted?
This trial is being conducted at Seattle, United States, London, United Kingdom.
Who is sponsoring the NCT07627074 clinical trial?
NCT07627074 is sponsored by Novo Nordisk A/S. The principal investigator is Clinical Transparency (dept. 2834) at Novo Nordisk A/S. The trial plans to enroll 35,000 participants.